2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH ANDREA APOLO
Immune Checkpoint Inhibitors Trials in Urothelial Cancer: Recent Updates and Future Outlook

VIEW ALL BLADDER CANCER VIDEOS

2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH TOM KEANE
A Look at Established Paradigms in Androgen Deprivation Therapy in the Treatment of Advanced Prostate Cancer

VIEW ALL ADV PROSTATE VIDEOS

2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH JEREMIE CALAIS
Molecular Imaging for Prostate Cancer Salvage Radiotherapy Planning

VIEW ALL IMAGING VIDEOS

2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH FRED SAAD
Delaying Disease Progression in Early Nonmetastatic CRPC Treatment

VIEW ALL nmCRPC VIDEOS

Featured Videos

Shockwave Therapy in the Treatment of Peyronie's Disease.

Peyronie's disease is an acquired condition of the connective tissue of the penis that affects 0.5-20.3% of the male population and is marked by fibrotic plaques in the tunica albuginea. It can result in penile curvature/deviation, painful erections, and sexual dysfunction. Several treatment modalities have been proposed, with studies from the past decade investigating extracorporeal shockwave therapy's (ESWT) potential efficacy in Peyronie's management.

To investigate the effects of ESWT on Peyronie's disease parameters such as penile curvature, plaque size, erectile function, and penile pain.

We reviewed the literature examining the effects of ESWT on Peyronie's disease.

The main outcome measures after receiving extracoporeal shockwave therapy included changes in degree of penile curvature, penile plaque size, International Index of Erectile Function-5 questionnaire score, and visual analogue scale score.

Randomized controlled trials examining the efficacy of ESWT in Peyronie's disease do not show a statistically significant benefit in curvature reduction, plaque size, or erectile function, although a recent meta-analysis demonstrates a benefit in plaque size reduction. A statistically significant reduction in penile pain has been observed across multiple studies.

Extracorporeal shockwave therapy may be beneficial in the management of Peyronie's disease for refractory penile pain and plaque size reduction. However, penile pain typically resolves spontaneously over time, and shockwave therapy can pose a substantial financial burden to patients. A multi-institutional randomized controlled trial with standardization of methods and strict inclusion criteria regarding disease duration would prove beneficial in determining the true efficacy of shockwave therapy in Peyronie's disease. Krieger JR, Rizk PJ, Kohn TP, et al. Shockwave Therapy in the Treatment of Peyronie's Disease. Sex Med Rev 2019;XX:XXX-XXX.

Sexual medicine reviews. 2019 Mar 26 [Epub ahead of print]

Jordan R Krieger, Paul J Rizk, Taylor P Kohn, Alexander Pastuszak

Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA., Department of Urology, University of Miami, Miami, FL, USA., Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Division of Urology, Department of Surgery, University of Utah School of Medicine, Salt Lake City, UT, USA. Electronic address: .

Conference Coverage
 
Recent data from conferences worldwide
Journals
Publications focusing on urologic cancer treatments through original manuscripts
Everyday Urology Volume 4 Issue 1

Everyday Urology™ - Oncology Insights

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe